Montelukast Sodium
Product Images NDC 70934-485

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Montelukast Sodium (NDC 70934-485). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Denton Pharma, Inc. Dba Northwind Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (70934 485 30 Master Bottle Label Approval Rev A 05 20)

Montelukast Sodium Chewable Tablets 5 mg label, showing a bottle with 30 tablets. The label includes storage instructions to keep at 25°C (77°F), protect from moisture and light, and keep out of children's reach. The product is labeled for pediatric patients aged 6-14 years, and manufactured by Denton Pharma, Inc. DBA Northwind Pharmaceuticals.*

FDA Label Image

Figure 1 (Montelukast Sodium Tablets And Chewable Tablets 1)

A line graph showing the change in height (cm) over weeks on treatment for three groups: Montelukast Sodium 5 mg, Beclomethasone 336 mcg, and Placebo. The x-axis represents weeks on treatment from -19 to 56, and the y-axis represents change in height from -3 to 7 cm. Three distinct lines track the height changes for each group over time.*

FDA Label Image

Chemical Structure (Montelukast Sodium Tablets And Chewable Tablets 2)

Chemical structure of montelukast sodium, showing its molecular framework with aromatic rings, a chlorine atom, a sodium carboxylate group, and other functional groups as depicted in the diagram.*

FDA Label Image

Figure 2 (Montelukast Sodium Tablets And Chewable Tablets 3)

A line graph illustrating mean percent change from baseline over 15 weeks in treatment comparing Montelukast Sodium and placebo groups. The x-axis represents weeks in treatment and washout period; the y-axis shows mean percent change from baseline. Montelukast Sodium data points are marked by filled circles, placebo by open squares, with error bars indicating variability. A washout period after week 12 is shown with a dashed line for Montelukast Sodium.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.